Azienda Socio Sanitaria Territoriale Della Valle Olona — Clinical Trial Site

17 Registered trials

9 Currently recruiting

Organisation

Azienda Socio Sanitaria Territoriale Della Valle Olona

Location

Busto Arsizio, Italy

Identifier

ORG-100049964

Address

Via Arnaldo Da Brescia 1, 21052, Italy

Departments

DIPARTIMENTO ONCOLOGICO
Div di Oncologia Medica
IT070A: Ematologia
Neurologia
Neurologia 2 – Sclerosi Multipla e Recupero Neurologico
Neurology
Neuroscience department
Oncologia
Oncology
PO Gallarate - Centro Studi Sclerosi Multipla - Neurologia 2 - Recupero Neurologico
S.C. Centro Sclerosi Multipla – Neurologia 2 (Gallarate)
S.C. Ematologia
SC Ematologia
SC Nefrologia e Dialisi
SC Pneumologia
U.O.C. DI CARDIOLOGIA

Clinical trials at this site (17)

Search interface

A multicenter open-label phase II study of Cemiplimab plus chemotherapy, selected on the basis of baseline cytidine deaminase activity, in a… Pending

2024-517799-40-00 Advanced squamous non-small cell lung cancer 4
Proof-of-Concept Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Efficacy Study of Intranasal Cenegermin in Adult Participants … Pending

2025-522692-29-00 Subacute Moderate to Severe Traumatic Brain Injury (TBI 4
IMPACT-AML: A RANDOMIZED PRAGMATIC CLINICAL TRIAL FOR RELAPSE OR REFRACTORY ACUTE MYELOID LEUKEMIA Recruiting

2024-514517-35-00 Acute myeloid leukemia 5 2025-02-27
A study to investigate the effect of AZD6793 in participants with moderate to very severe chronic obstructive pulmonary disease Recruiting

2025-520473-40-00 Moderate to Very Severe Chronic Obstructive Pulmonary D 4 2025-09-29
Impact of Patiromer treatment on dietary Potassium intake restriction and health-related quality of life and nutrition in patients on Chroni… Recruiting

2025-521378-33-00 End Stage Kidney Disease on chronic dialysis therapy 5 2025-07-31
A trial to learn how well surovatamig (AZD0486) works and how safe it is in adults with certain blood cancers Recruiting

2023-505789-27-00 Relapsed or Refractory Non-Hodgkin Lymphoma 4 2025-04-14
COLchicine and Thiamine in Heart Failure due to Ischemic Heart Disease (COLT-HF) Recruiting

2023-506675-96-00 Heart Failure 5 2025-01-23
A Phase 3, randomized, open-label, multicenter, controlled study to evaluate the efficacy and safety of zanidatamab in combination with phys… Recruiting

2023-508960-31-00 Metastatic HER2-positive breast cancer 5 2024-12-03
A Phase 1/2 study of Enzomenib (DSP-5336) in Adult Patients with Acute leukemia Recruiting

2022-502741-10-00 Acute Leukemia with Mixed Lineage Leukemia (MLL)-rearra 7 2024-01-26
Bacille Calmette-Guérin (BCG) vaccine in Radiologically Isolated Syndrome (RIS) Recruiting

2024-518901-16-00 RIS (Radiologically Isolated Syndrome) 4 2019-07-29
Efficacy and safety study of frexalimab (SAR441344) in adults with nonrelapsing secondary progressive multiple sclerosis Ended

2023-504359-29-01 Multiple sclerosis 5 2024-12-11
A Rollover Study to Evaluate the Long-Term Safety and Efficacy of Ocrelizumab In Patients with Multiple Sclerosis Ended

2023-505974-14-00 Multiple Sclerosis (MS) 5 2022-06-23
Clinical study testing the efficacy and safety of Ravulizumab in pediatric patients with NMOSD Ended

2023-508534-33-00 Neuromyelitis Optica Spectrum Disorder (NMOSD) 10 2022-06-16
Shortened vs standard chemotherapy combined with immunotherapy for the initial treatment of patients with high tumor burden Follicular Lymph… Ended

2024-511636-27-00 Follicular Lymphoma 5 2021-12-01
A Study to Evaluate the Efficacy, Safety and Pharmacokinetics of a Higher Dose of Ocrelizumab in Adults With Primary Progressive Multiple Sc… Ended

2023-506515-18-00 Primary Progressive Multiple Sclerosis (PPMS) 5 2020-10-23
A randomized phase III multicenter trial assessing efficacy and toxicity of a combination of Rituximab and Lenalidomide (R2) vs Rituximab al… Ended

2024-511640-11-00 Follicular lymphoma 5 2014-05-15
A Phase III Prospective Double Blind Placebo Controlled Randomized Study of Adjuvant MEDI4736 in Completely Resected Non-Small Cell Lung Can… Ended

2024-517856-36-00 Completely resected primary stage IB (≥ 4cm), II and II 5 2015-03-09